S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:ASLN

ASLAN Pharmaceuticals Stock Forecast, Price & News

$1.23
-0.06 (-4.65%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.21
$1.30
50-Day Range
$1.23
$2.12
52-Week Range
$1.21
$6.75
Volume
310,719 shs
Average Volume
1.23 million shs
Market Capitalization
$46.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.4
30 days | 90 days | 365 days | Advanced Chart
Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


ASLAN Pharmaceuticals logo

About ASLAN Pharmaceuticals

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and AhR Antagonist. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASLN
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$3 million
Book Value
($0.32) per share

Profitability

Net Income
$-16.20 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$46.73 million
Optionable
Not Optionable

Company Calendar

Last Earnings
10/25/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/28/2022

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

782nd out of 1,390 stocks

Pharmaceutical Preparations Industry

372nd out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












ASLAN Pharmaceuticals (NASDAQ:ASLN) Frequently Asked Questions

Is ASLAN Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASLAN Pharmaceuticals stock.
View analyst ratings for ASLAN Pharmaceuticals
or view top-rated stocks.

How has ASLAN Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

ASLAN Pharmaceuticals' stock was trading at $1.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ASLN stock has decreased by 22.6% and is now trading at $1.23.
View which stocks have been most impacted by COVID-19
.

Are investors shorting ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 155,900 shares, a decrease of 56.6% from the October 31st total of 358,900 shares. Based on an average trading volume of 1,060,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.3% of the company's shares are sold short.
View ASLAN Pharmaceuticals' Short Interest
.

When is ASLAN Pharmaceuticals' next earnings date?

ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, April 28th 2022.
View our earnings forecast for ASLAN Pharmaceuticals
.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) issued its earnings results on Monday, October, 25th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01.
View ASLAN Pharmaceuticals' earnings history
.

What price target have analysts set for ASLN?

3 Wall Street analysts have issued 12-month price objectives for ASLAN Pharmaceuticals' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate ASLAN Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 550.4% from the stock's current price.
View analysts' price targets for ASLAN Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ASLAN Pharmaceuticals' key executives?

ASLAN Pharmaceuticals' management team includes the following people:
  • Carl Aslan Jason Morton Firth, Chief Executive Officer & Director
  • Kiran Kumar Asarpota, Chief Operating Officer & Head-Finance
  • Kenneth Kobayashi, Chief Medical Officer
  • Stephen Doyle, Chief Business Officer
  • Ferda Cevikbas, Executive Director & Head-Translational Science

What other stocks do shareholders of ASLAN Pharmaceuticals own?

When did ASLAN Pharmaceuticals IPO?

(ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN Pharmaceuticals' stock symbol?

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

Who are ASLAN Pharmaceuticals' major shareholders?

ASLAN Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (3.86%), Tang Capital Management LLC (2.57%), Affinity Asset Advisors LLC (0.66%), Point72 Asset Management L.P. (0.66%), Morgan Stanley (0.63%) and MYDA Advisors LLC (0.62%).

Which institutional investors are selling ASLAN Pharmaceuticals stock?

ASLN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, and Two Sigma Advisers LP.

Which institutional investors are buying ASLAN Pharmaceuticals stock?

ASLN stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Point72 Asset Management L.P., Affinity Asset Advisors LLC, Millennium Management LLC, Citadel Advisors LLC, Barclays PLC, Geode Capital Management LLC, and MYDA Advisors LLC.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ASLAN Pharmaceuticals' stock price today?

One share of ASLN stock can currently be purchased for approximately $1.23.

How much money does ASLAN Pharmaceuticals make?

ASLAN Pharmaceuticals has a market capitalization of $46.73 million and generates $3 million in revenue each year. The company earns $-16.20 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does ASLAN Pharmaceuticals have?

ASLAN Pharmaceuticals employs 2,020 workers across the globe.

What is ASLAN Pharmaceuticals' official website?

The official website for ASLAN Pharmaceuticals is www.aslanpharma.com.

Where are ASLAN Pharmaceuticals' headquarters?

ASLAN Pharmaceuticals is headquartered at 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920.

How can I contact ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at (656) 222-4235, via email at [email protected], or via fax at 65-6225-2419.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.